CR2 and dendritic cell sarcoma: SRGN, together with CD21 and CD35, was negative in all non-FDC-S tumors; FDCSP, expressed by one case of SNHP, one case of SS and one case of interdigitating dendritic cell sarcoma, still showed a better performance than other widely used FDC markers.